Borwein, Jonathan, and Lewis, Adrian
Please contact us to get detection data for reference
(Source: Long-term GLP-1 safety review, June 2026) There Is No Evidence Supporting a Hard Time Limit on Treatment A frequent patient concern is that GLP-1s cannot be safe indefinitely
Hypogonadism refers to a condition where the body produces insufficient levels of testosterone, the hormone responsible for male sexual development, muscle mass, bone density, and overall well-being
Transitioning from weight loss to maintenance Determining goal weight achievement: Lost 10-12% body weight (cagrilintide alone) Lost 15-25% body weight (CagriSema) Weight stable for 4-8 weeks Satisfied with current weight Ready to focus on maintenance Maintenance dose options comparison: Option 1: Continue same dose Keep cagrilintide at 2.4mg weekly Ensures no regain Most conservative approach Highest cost Option 2: Reduce dose slightly Decrease to 1.8-2.0mg weekly Monitor weight for 4 weeks If stable, maintain If gaining, increase back 20-25% cost savings Option 3: Try every 10 days Instead of weekly, inject every 10 days Effectively 30% dose reduction Some maintain weight this way Requires close monitoring Recommendation: Try Option 2 first (reduce to 1.8-2.0mg)
